See the end of this post for information about additional trials that are using Ipilimumab and currently recruiting men with hormone refractory prostate cancer. A multi-site PHASE I study with 33 men has found that a drug called Ipilimumab, also known as MDX-010, has been shown to be able to stimulate the body's own immune [...]
Highlights of the advance prostate cancer session meeting in Orlando, Florida included Abstract 531 which evaluated 6,437 men who had received androgen deprivation therapy for more than 1.5 years. According to the abstract Dementia and COPD were the main non-GU side effects associated with long-term androgen deprivation. Presented by Ziya Kirkall, MD, at the Annual [...]
"All-cause mortality” or death by all causes has been shown to increase in men who have deficiencies of testosterone. A new study, conducted in Germany, recently came to this conclusion. In this study, The Study of Health in Pomerania (SHIP), the researchers looked at death rates from any cause in almost 2,000 men aged 20 [...]
Researchers at Weill Cornell Medical College, New York, have found the hormone estrogen plays a major role in about half of all prostate cancers. Their findings were published in the May 27 online edition of the Journal of the National Cancer Institute. They have found that the estrogen-linked signaling helps drive a discrete and aggressive [...]
In honor of the Dev and I being in Time magazine last year my wife?purchased a subscription for me as a gift. Now I spend a couple off days a week reading the articles on the subway as I commute. I read from cover to cover and I am consistently entertained and informed. Every so [...]